Page last updated: 2024-11-12

eriocalyxin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

eriocalyxin B: isolated from Isodon Eriocalyx; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
IsodongenusA plant genus of the family LAMIACEAE used in TRADITIONAL CHINESE MEDICINE.[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID SourceID
PubMed CID16202215
CHEMBL ID2088267
SCHEMBL ID22526009
MeSH IDM0506007

Synonyms (13)

Synonym
eriocalyxin b
CHEMBL2088267
84745-95-9
AKOS032948099
BCP23955
nsc 637462; rabdosianone; rabdosianone i
CS-0019713
HY-N2303
(1s,2s,5r,8s,9s,10s,11r)-9,10-dihydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadec-13-ene-7,15-dione
SCHEMBL22526009
MS-25286
DTXSID801317705
eriocalyxinb

Research Excerpts

Overview

Eriocalyxin B (EriB) is a natural medicine that antagonizes inflammation. It is purified from Isodon eriocalyx var.

ExcerptReferenceRelevance
"Eriocalyxin B (EriB) is a natural medicine that antagonizes inflammation."( Eriocalyxin B ameliorated Crohn's disease-like colitis by restricting M1 macrophage polarization through JAK2/STAT1 signalling.
Cheng, Y; Geng, Z; Huang, J; Li, J; Li, Q; Li, Y; Song, X; Wang, L; Wang, Y; Wu, X; Xu, M; Yang, Z; Zhang, H; Zhang, J; Zhang, X; Zhao, T; Zuo, L, 2023
)
3.07
"Eriocalyxin B (EriB) is a natural diterpenoid purified from Isodon eriocalyx var. "( Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
Chen, QS; Chen, SJ; Chen, Z; Jiang, XX; Shen, ZX; Shi, WY; Sun, HD; Wang, L; Zhang, YW; Zhao, WL, 2010
)
3.25

Pharmacokinetics

ExcerptReferenceRelevance
"The purpose of this study was to determine EriB in plasma by using the method of HPLC and collect the preclinical pharmacokinetic parameters of EriB."( A validated HPLC method for the determination of eriocalyxin B in plasma and its application to pharmacokinetic studies.
Chen, HY; Chen, JX; Cui, Z; Sun, JH; Wang, Z; Wu, H; Yuan, Q, 2012
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID683414Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx.
AID683413Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx.
AID683415Cytotoxicity against human A549 cells after 48 hrs by MTT assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx.
AID683416Cytotoxicity against human SW480 cells after 48 hrs by MTT assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx.
AID683412Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Laxiflorolides A and B, epimeric bishomoditerpene lactones from Isodon eriocalyx.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.45)18.2507
2000's5 (17.24)29.6817
2010's18 (62.07)24.3611
2020's5 (17.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.63 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index5.40 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]